Enhancing the efficacy and ease of application of existing endemic livestock disease vaccines via novel adjuvants and delivery systems

通过新型佐剂和输送系统提高现有家畜地方病疫苗的功效和易用性

• 批准号: BB/W02053X/1
• 负责人: Simon Graham
• 金额: $ 25.47万
• 依托单位: The Pirbright Institute
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FW02053X%2F1
• 关键词: Enhancing; efficacy; ease; application; existing

Endemic infectious diseases of livestock cause major financial losses and threaten food security, animal welfare, and public health. Vaccination is a highly cost-effective tool to help prevent, control, and eradicate diseases. However, many vaccines currently used to prevent and control endemic livestock diseases (ELD) are suboptimal. While they may help protect animals from suffering disease, they may not effectively control the disease-causing microbe (pathogen). This allows pathogens to be transmitted to other animals and potentially to mutate as they replicate, which makes them more resistant to vaccines. In addition to these inherent shortcomings, there are practical issues of storage and administration of vaccines on-farm that require improvement to optimise the benefits to users and animals from vaccination. This project aims to take advantage of recent advances in vaccine formulation and delivery to devise strategies that could make ELD vaccines more effective and easier to administer. We will use vaccines for control of the porcine reproductive and respiratory syndrome virus (PRRSV) as a test case. PRRSV is responsible for one of the most economically important diseases affecting the global pig industry and is a priority disease for the UK pig sector. Vaccination is a cornerstone of PRRS control, but improved vaccines are urgently required. The project is a collaboration between leading UK veterinary bioscience, social science, and stakeholders. Using a co-design and participatory approach, we will work with vaccine companies and selected producers, their veterinarians, and wider stakeholders to ensure that the research addresses their concerns and meets their needs with respect to on-farm delivery and use of vaccines to support a drive for improvement. By taking soundings from stakeholders, we will seek to understand, and therefore take into account, their concerns and needs as regards on-farm vaccine use. We will explore issues around the acceptance of new vaccines and delivery devices. We will then conduct a 'proof-of-concept' study to test whether new formulations of an existing PRRSV vaccine, delivered by innovative devices, provides enhanced protection, whilst being simple and practical to administer. Finally, we will take our findings back to producers via virtual workshops to obtain their feedback, which will help shape the future research and development of the approaches. This project will help deliver improved vaccines and their adoption, which will aid the prevention and control of ELD. Consequently, this project should lead to enhanced livestock health, welfare, and productivity, and reduced antimicrobial use. Whilst the most immediate benefit will likely be in the control of PRRSV, this project has the potential to have a wide impact by informing efforts to develop improved vaccine/formulations for other diseases of both livestock and humans.

牲畜的地方性传染病会造成重大财务损失，并威胁粮食安全，动物福利和公共卫生。疫苗接种是一种高度成本效益的工具，可帮助预防，控制和消除疾病。但是，许多目前用于预防和控制地方性牲畜疾病（ELD）的疫苗是次优的。尽管它们可能有助于保护动物免受疾病的侵害，但它们可能无法有效控制引起疾病的微生物（病原体）。这允许病原体传播给其他动物，并可能在复制时突变，从而使它们对疫苗具有更大的抵抗力。除了这些固有的缺点外，还需要改进农场疫苗的储存和给药，以优化从疫苗接种中对用户和动物的收益。该项目旨在利用疫苗配方和交付方面的最新进展，以制定可能使ELD疫苗更有效和易于管理的策略。我们将使用疫苗来控制猪生殖和呼吸道综合征病毒（PRRSV）作为测试用例。 PRRSV负责影响全球猪工业的最重要的疾病之一，是英国猪行业的优先疾病。疫苗接种是PRRS控制的基石，但迫切需要改善的疫苗。该项目是英国领先的兽医生物科学，社会科学与利益相关者之间的合作。使用共同设计和参与的方法，我们将与疫苗公司和选定的生产者，其兽医以及更广泛的利益相关者合作，以确保研究能够解决他们的关注点，并满足他们在农场交付和使用疫苗方面满足他们的需求改进的动力。通过吸收利益相关者的声音，我们将寻求理解，并考虑到农场疫苗使用方面的关注和需求。我们将探讨接受新疫苗和送货设备的问题。然后，我们将进行一项“概念验证”研究，以测试创新设备提供的现有PRRSV疫苗的新配方是否提供了增强的保护，同时简单而实用。最后，我们将通过虚拟研讨会将发现回到生产者，以获得他们的反馈，这将有助于塑造方法的未来研究和开发。该项目将有助于提供改进的疫苗及其采用，这将有助于预防和控制ELD。因此，该项目应导致牲畜健康，福利和生产力增强，并降低抗菌素的使用。尽管最直接的收益可能是由PRRSV控制的，但该项目有可能通过告知为牲畜和人类的其他疾病开发疫苗/配方的努力而产生广泛影响。